Experts believe a wider spat with Europe would be much more damaging than the current tit-for-tat with China.Traderead more
After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Markets pay particular attention to Italy's spending, given its public debt pile. This stands at above 130% of its growth rate, one of the highest in the world.Politicsread more
Flight bookings to Hong Kong have fallen 10%, hit by the unrest in the city, said Alan Joyce, the chief executive of Australian carrier Qantas Airways.Airlinesread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
drags@ (Adds background, details on second quarter)
Aug 6 (Reuters) - Drugmaker Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing increasing uncertainties tied to opioid litigation.
Mallinckrodt, like other pharmaceutical companies that make opioid drugs, is facing lawsuits that have alleged that it contributed to the addiction epidemic in the United States through its marketing and promotion practices.
The company has also struggled with falling prices for generic drugs.
Mallinckrodt in June tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed Acthar gel, its expensive treatment for a rare infant seizure disorder and multiple sclerosis.
Shares of the company have plunged nearly 60% this year.
Mallinckrodt had previously said it would spin off the generics unit and it would retain its constipation medicine Amitiza as part of its specialty branded drugs business.
The company said on Tuesday it would continue to consider a "range of options" to ultimately separate the generics business, consistent with its announced strategy.
Mallinckrodt also reported second quarter net income of $6.8 million, or 8 cents per share, down from $15.6 million, or 19 cents per share, a year earlier, due to an impairment charge.
The company said sales of Acthar fell 9.1% to $266.4 million, hurt by reimbursement challenges and insurer scrutiny of specialty pharmaceutical spending. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)